Tech giants have seized a huge share of the health and preventive technology market, but how could partnerships between the pharmaceutical and tech industries benefit patients and healthcare systems?

To be honest, my initial foray into the field of diabetes was by chance, as I took on the management of diabetes at the practice when I joined as a salaried general practitioner.

AN INTERNATIONAL COLLECTIVE of oncology clinicians and researchers came together to share the most recent updates in patient care and…

Metastatic collecting ducts carcinoma is biologically poorly characterised and under-represented in prospective randomised trials.

The symposium featured three talks and a live Q&A session. First, the current patient journey and standards of care in oesophageal cancer…

Opening the session, Calvo presented a compelling and balanced case about the potential that Phase 0 (Ph0) trials hold for increasing…

Colorectal cancer (CRC) is the second most common cause of cancer-related death in the USA. Despite improvements in screening rates and in the overall survival (OS) of patients with localised and advanced disease over the past few decades, the 5-year OS of patients with metastatic disease is still extremely poor and estimated to be approximately 15%.

Colorectal cancer (CRC) is the third most common cancer in Québec, Canada…

The liver is the most common site for colorectal cancer (CRC) metastases, accounting for 80% of patients with Stage IV CRC and 40% as the only site of distant disease. Of the patients with CRC, 20–25% present with synchronous metastases and 50–60% will develop metachronous disease. Liver metastases develop in the absence of lymph node involvement and, presumably, this occurs via the haematogenous route (the portal circulation) in gastrointestinal tumours from where tumour cells can embolise via the mesenteric veins.